Anavex Life Sciences shares rise 10.34% intraday after presenting new AD-004 IIb/III trial data on Blarcamesine showing brain volume preservation in early Alzheimer's patients, with 77.4 weeks saved over 144 weeks of treatment.

Anavex Life Sciences surged 10.34% intraday, driven by new data from its AD-004 IIb/III trial presented at the AD/PD 2026 meeting, showing a consistent association between oral Blarcamesine treatment and brain volume preservation in early Alzheimer’s patients. Long-term data indicated a 77.4-week preservation over 144 weeks of treatment, with the meeting also highlighting the drug’s convenience for patients/families and its MRI-clinical endpoint correlation.